Status:
COMPLETED
A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
Lead Sponsor:
GlaxoSmithKline
Conditions:
Social Anxiety Disorder
Anxiety Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
Eligibility Criteria
Inclusion
- Patients with Generalized Social Anxiety Disorder as the primary diagnosis.
- If female, must commit to consistent and correct use of an acceptable method of birth control.
Exclusion
- Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening.
- Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder.
- Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal.
- Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months.
- Patients with an unstable medical disorder.
- Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study.
- Patients who are taking other psychoactive medications.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT00273039
Start Date
August 1 2005
End Date
September 1 2006
Last Update
October 26 2016
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Beverly Hills, California, United States, 90210
2
GSK Investigational Site
Burbank, California, United States, 91506
3
GSK Investigational Site
Jacksonville, Florida, United States, 32216
4
GSK Investigational Site
Miami, Florida, United States, 33125